Arena Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 76   

Articles published

ARNA 4.77 -0.08 (-1.65%)
price chart
Arena Pharmaceuticals to Host Corporate Update and Financial Results ...
SAN DIEGO, July 25, 2014 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) today announced that it will provide a corporate update and report second quarter 2014 financial results before the NASDAQ Global Select Market opens on Friday, ...
Arena Sees Belviq Sales Climb Despite Seasonality (ARNA)  Seeking Alpha (registration)
Related articles »  
Stocks to Track - Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Extreme ...
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) recently reported that its wholly owned subsidiary, Arena Pharmaceuticals GmbH, has entered into an exclusive marketing and supply agreement for BELVIQ� (lorcaserin HCl) with Teva Pharmaceutical ...
Related articles »  
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Sells Marketing And Distribution ...
Dallas, Texas 07/22/2014 (ustradevoice) - Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)'s wholly owned subsidiary Arena Pharmaceuticals GmbH has undertaken a marketing and supply deal for BELVIQ� with Abic Marketing Limited, the local Israel-based ...
Arena Pharmaceuticals Enters into Marketing and Supply Agreement for BELVIQ ...  Wall Street Journal
Teva's subsidiary, Abic to market Arena Pharma's Belviq in Israel  pharmabiz.com
Related articles »  
Arena Pharmaceuticals Inc. Still Down After CEO's Sale
"Week-over-week prescriptions are increasing. We're very excited about that. And we expect those prescriptions to continue to increase as, yet a larger salesforce, goes into the field in the next few weeks.
Why Arena Pharmaceuticals (ARNA) Stock Is Dropping Today
NEW YORK (TheStreet) -- Arena Pharmaceuticals (ARNA_) shares are plummeting, down -8.1% to $5.37, on Monday after CEO Jack Lief sold 223,525 shares of the company at an average price $5.85 for a total transaction of $1,307,621.25, according to an ...
Arena Stock Takes A Tumble � CEO Sells Shares, Investor Confidence Falls  Bidness Etc
Arena chief's stock sale invites criticism (ARNA)  Seeking Alpha
Related articles »  
Active Watch List - Arena Pharmaceuticals (NASDAQ:ARNA), SanDisk Corp ...
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) stock lost 9.42% of their value after Jack Lief, the CEO of the company, sold approximately 40% of his total stake in the company.
How Biotech Stocks React on News- Arena Pharmaceuticals, Inc. (NASDAQ ...  eMarketsDaily
Morning Watch List - VIVUS, Inc. (NASDAQ:VVUS), Arena Pharmaceuticals ...  WallStreet Scope
Related articles »  
Best Stocks � DR Horton, Inc. (NYSE:DHI), Arena Pharmaceuticals, Inc ...
D.R. Horton Inc., (NYSE:DHI) the largest U.S. homebuilder by revenue, fell the most in almost five years after saying it's increasing incentives to boost orders, reducing profitability as the broader new-home market stumbles.
News Recap: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Geron Corporation ...
Lakeway, NY - (MARKET NEWS CALL) - 7/22/2014� Specialpennystockalert.com, an investment community with a special focus on updating investors with recent news on the U.S.
Eye-Catching Stocks � Arena Pharmaceuticals, Inc.(NASDAQ:ARNA), EXCO ...
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) decreased -0.58% at the price of $4.85 recently on a traded volume of 1.84 million shares, in comparison to 5.63 million shares of average trading volume.
Hot Stocks � VIVUS Inc. (NASDAQ:VVUS), Arena Pharmaceuticals (NASDAQ ...
On JULY 18, Shares of VIVUS Inc (NASDAQ:VVUS) were the target of a large decrease in short interest in June. As of June 30th, there was short interest totalling 37,987,360 shares, a decrease of 6.4% from the June 13th total of 40,597,345 shares, ...